Checkpoint inhibitors are drugs that target checkpoint proteins on immune cells. These proteins, such as PD-1, PD-L1, and CTLA-4, normally keep immune responses in check to prevent autoimmunity. However, cancer cells often exploit these checkpoints to evade immune detection. By blocking these proteins, checkpoint inhibitors free up T cells to attack cancer more effectively.
